Showing results (871-880 of 964) with videos related to
Sort By:
Pageof 97
Plant Physiology|April 28, 2017
Insights into the Evolution of Hydroxyproline-Rich Glycoproteins from 1000 Plant TranscriptomesKim L Johnson, Andrew M Cassin, Andrew Lonsdale, et al.Proceedings of the National Academy of Sciences of the United States of America|October 7, 2015
Algal ancestor of land plants was preadapted for symbiosisPierre-Marc Delaux, Guru V Radhakrishnan, Dhileepkumar Jayaraman, et al.Annals of Internal Medicine|August 19, 2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized TrialGregory J Dore, Frederick Altice, Alain H Litwin, et al.Journal of Hepatology|June 8, 2023
Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trialsEd Gane, Young-Suk Lim, Jae B Kim, et al.The American Journal of Gastroenterology|August 10, 2023
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone SafetyHenry L Y Chan, Maria Buti, Young-Suk Lim, et al.Gastroenterology|August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 TrialEdward J Gane, Kris V Kowdley, David Pound, et al.JHEP Reports : Innovation in Hepatology|September 29, 2023
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis BYoung-Suk Lim, Henry L Y Chan, Sang Hoon Ahn, et al.Hepatology (Baltimore, Md.)|March 3, 2020
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled TrialKeyur Patel, Stephen A Harrison, Magdy Elkhashab, et al.The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialHenry L Y Chan, Scott Fung, Wai Kay Seto, et al.Bioorganic & Medicinal Chemistry Letters|January 27, 2004
Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituentUday R Khire, Donald Bankston, James Barbosa, et al.Pageof 97